Results 161 to 170 of about 21,507 (209)
Some of the next articles are maybe not open access.
Cofactor of the “Lupus Anticoagulant”
Thrombosis and Haemostasis, 1974SummaryNormal plasma contains an activity known as cofactor which further lengthens the clotting time of the plasma of some patients with the “lupus anticoagulant.55 Cofactor has been characterized as either prothrombin or a gamma globulin. Our findings indicate that cofactor has the following properties: stable at room temperature but largely ...
G E, Rivard, S, Schiffman, S I, Rapaport
openaire +2 more sources
Standardization of lupus anticoagulant. The Lupus Anticoagulant Sensitivity Index (LASI)
Lupus, 2012Results for lupus anticoagulant (LA) are expressed as ratio of patient-to-normal clotting times (LA-ratio) according to the equation LA-ratio = (PatientClotting time/NormalClotting time). However, numerical results vary according to the method used for testing, thus making difficult the between-method and between-laboratory comparison of results.
Tripodi A +2 more
openaire +2 more sources
Lupus anticoagulants in children
Current Opinion in Hematology, 2003Lupus anticoagulant and ACAs are made up of heterogeneous IgG and IgM antibodies that prolong in vitro clotting times and are associated with increased risks of venous and arterial thrombosis, recurrent fetal loss, and autoimmune thrombocytopenia and anemia.
Michael, Briones, Thomas, Abshire
openaire +2 more sources
2013
Antiphospholipid antibodies are a heterogenous group of autoantibodies directed against glycoproteins in concert with anionic phospholipids. In clinical laboratory practice, antiphospholipid antibody evaluations usually consist of a combination of the following: anticardiolipin antibody assay, anti-beta 2 glycoprotein I assay, and at least two lupus ...
Karen, Moffat +2 more
openaire +2 more sources
Antiphospholipid antibodies are a heterogenous group of autoantibodies directed against glycoproteins in concert with anionic phospholipids. In clinical laboratory practice, antiphospholipid antibody evaluations usually consist of a combination of the following: anticardiolipin antibody assay, anti-beta 2 glycoprotein I assay, and at least two lupus ...
Karen, Moffat +2 more
openaire +2 more sources
Screening for the lupus anticoagulant
La Ricerca in Clinica e in Laboratorio, 1989The lupus anticoagulant may be defined as an immunoglobulin (IgG, IgM or both) which interferes with one or more of the in vitro phospholipid-dependent tests of coagulation. For many years, lupus anticoagulants were regarded as a laboratory nuisance; consequently, reagents were often selected on the basis of insensitivity to lupus anticoagulants ...
openaire +2 more sources
Detection of lupus anticoagulants
Clinical Reviews in Allergy & Immunology, 1995M H, Horellou, M M, Samama
openaire +2 more sources
Lupus anticoagulant and pregnancy
American Journal of Obstetrics and Gynecology, 1986B, Spitz, F A, Van Assche, J, Vermylen
openaire +2 more sources
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Nature Medicine, 2022Andreas Mackensen, Sebastian Boeltz
exaly
Rinsho byori. The Japanese journal of clinical pathology, 1993
Lupus anticoagulant (LAC) is an acquired inhibitor of prothrombin activator complex, which probably interferes with the phospholipid portion. Characteristically, LAC prolongs the partial prothrombin time, but only slightly prolongs the prothrombin time. It is a paradoxical fact that LAC is characterized by thrombosis.
A, Yoshida, K, Morozumi
openaire +1 more source
Lupus anticoagulant (LAC) is an acquired inhibitor of prothrombin activator complex, which probably interferes with the phospholipid portion. Characteristically, LAC prolongs the partial prothrombin time, but only slightly prolongs the prothrombin time. It is a paradoxical fact that LAC is characterized by thrombosis.
A, Yoshida, K, Morozumi
openaire +1 more source